- Conditions
- Barth Syndrome
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 4,209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
- Interventions
- Pasireotide LAR, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Eye Disease, TED
- Interventions
- Satralizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • La Jolla, California • Wichita, Kansas + 8 more
- Conditions
- Sepsis, Community Acquired Pneumonia (CAP)
- Interventions
- OPT101, Placebo
- Drug · Other
- Lead sponsor
- Op-T LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Anterior Cruciate Ligament
- Interventions
- Gel-One, Saline Placebo
- Drug · Other
- Lead sponsor
- Cale Jacobs, PhD
- Other
- Eligibility
- 14 Years to 33 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Rheumatoid Arthritis
- Interventions
- Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
- Drug
- Lead sponsor
- Oryn Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tustin, California • Miami, Florida
- Conditions
- Healthy Participants
- Interventions
- SP16, Placebos
- Drug
- Lead sponsor
- Serpin Pharma, LLC
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hypogonadotropic Hypogonadism, Type 2 Diabetes
- Interventions
- testosterone, clomiphene, placebo
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Carboplatin, Cisplatin, Docetaxel, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Influenza A
- Interventions
- AZD4117, AZD5315, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more
- Conditions
- Moderate-to-severe Atopic Dermatitis
- Interventions
- CBP-201, placebo
- Drug
- Lead sponsor
- Connect Biopharm LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 38
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more
- Conditions
- Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
- Interventions
- BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Los Alamitos, California
- Conditions
- Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
- Interventions
- Apraglutide, Placebo
- Drug
- Lead sponsor
- VectivBio AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 24
- States / cities
- Covina, California • Brandon, Florida • DeBary, Florida + 20 more
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Interventions
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
- Conditions
- Hypogonadism, Male, Fatigue Syndrome, Chronic
- Interventions
- Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo
- Drug · Other
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 54 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Short Bowel Syndrome
- Interventions
- apraglutide
- Drug
- Lead sponsor
- VectivBio AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Biological · Drug
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more
- Conditions
- Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
- Interventions
- Parenteral cysteine-HCl supplementation, Placebo - added premasol
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Stroke, Muscle Spasticity
- Interventions
- Botox (botulinum toxin)
- Drug
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- LY2189265, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 31
- States / cities
- Peoria, Arizona • Anaheim, California • Lancaster, California + 28 more
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Tirzepatide, Placebo (saline)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more
- Conditions
- Hepatitis E, Immunisation
- Interventions
- HEV 239, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia